The Real Cost of a Missed Doctor Visit

Field force managers track call average and coverage percentage religiously. Almost nobody tracks the second-order cost of a missed visit: what happens to prescription behaviour in the two to three weeks after a doctor expected a rep and didn't get one.

The decay curve is faster than most brand teams assume

Doctor recall for a detailed message drops sharply after 10-12 days without reinforcement, internal tracking at several mid-size Indian pharma companies puts unprompted brand recall down by roughly 30% within two weeks of a missed cycle. For a therapy area with three or four competing brands actively detailing the same doctor, that gap is exactly when share shifts. It's rarely reported that way in the monthly review, because the sales number that quarter often still looks fine, the erosion shows up one or two quarters later, blended into "market dynamics."

Missed visits cluster, they don't distribute randomly

The instinct is to assume a missed call is a random, one-off event, a rep was sick, a doctor's clinic was shut. In practice, missed visits cluster around the same 15-20% of doctors: the busiest, highest-prescribing ones, precisely because they're hardest to catch. A doctor who sees 150 patients a day and closes his OPD by 1pm is disproportionately likely to get skipped when a rep is running behind schedule, and disproportionately valuable when he doesn't get skipped.

What actually gets measured vs what matters

• •Call average: tracks whether a rep did enough visits, not which ones
• •Coverage percentage: tracks whether a doctor was visited once in a cycle, not whether the timing mattered
• •Rarely tracked: whether high-value doctors were the ones who slipped

A field team hitting 92% coverage can still be leaking revenue if the 8% miss rate is concentrated among the top decile of prescribers. Fixing this isn't about pushing reps to work harder, most are already stretched across more doctors than any global benchmark recommends. It's about knowing, in near real time, which missed visits are cosmetic and which ones actually move next quarter's number. That distinction is one most reporting stacks in Indian pharma still can't make.